ASHP's virtual House of Delegates recently approved professional policies on gene therapy, unit dose packaging availability, and drug dosing in conditions that modify pharmacokinetics or pharmacodynamics, among other topics. Following discussion in the House of Delegates community on ASHP Connect, delegates voted online during the week of March 16-
EVENT: Health and Human Services Department; Food and Drug Administration holds a meeting on "Evaluating Inclusion and Exclusion Criteria in Clinical Trials." LOCATION: National Press Club, 529 14th Street NW, Washington, D.C.. CONTACT: Dianne Paraoan, 301-796-2500, Dianne.Paraoan@fda.hhs.gov.
The Director General, National Agency for the Control of Aids, Dr Sani Aliyu has said HIV/AIDS should be integrated into the healthcare service and not treated as separate disease. Dr Sani who made this known during an interview said, funding for HIV/AIDS should not be separate, but be inculcated into the healthcare budget. Dr Sani also said NACA w
KENILWORTH, N.J.,& BRUSSELS Merck, known as MSD outside the United States and Canada, and the European Organisation for Research and Treatment of Cancer, today announced findings from the Phase 3 EORTC1325/KEYNOTE-054 trial investigating KEYTRUDA , Merck s anti-PD-1 therapy, as adjuvant therapy in resected, high-risk stage III melanoma.
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Data detailed on Epidemiology have been presented. Our news editors obtained a quote from the research from Yale University, "This study aims to compare the treatment effects among pivotal trials supporting FDA approval of novel therapeutics based on surrogate markers of disea
By a News Reporter-Staff News Editor at Heart Disease Weekly From Alexandria, Virginia, NewsRx journalists report that a patent by the inventors Bai, Hua; Zhao, Xuyang; Zhang, Yuncai; Li, Xufei; Zhang, Yong; Xu, Dezhou; Zhang, Li; Xu, Xiaojie; Zhu, Qifeng; Wang, Xiaoming; Yang, Zhiqing; Zhong, Zehua; Zhang, Jian, filed on June 5, 2015, was publis
Frank Wagner, a Republican, is the latest member of his party to express his openness to expanding Medicaid in Virginia to cover an estimated 400,000 people now without insurance. In a column published in The Virginian-Pilot, Wagner said he believes a compromise is possible between Democrats who advocate for expansion, including Gov. Ralph Northam,
Report Summarizes Heart Failure Study Findings from Brigham and Women's Hospital. By a News Reporter-Staff News Editor at Heart Disease Weekly Investigators publish new report on Heart Disorders and Diseases- Heart Failure. Our news journalists obtained a quote from the research from Brigham and Women's Hospital, "We utilized data from the CHARM
By a News Reporter-Staff News Editor at Heart Disease Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Ternes, David J.; Thakur, Pramodsingh Hirasingh; Ruble, Stephen B., filed on August 11, 2017, was made available online on March 29, 2018. News editors obtained the following quote from the backg
April 14 UnitedHealth Group is pushing back against a federal whistleblower case, alleging the Justice Department's arguments would mean the agency that runs the federal Medicare program has broken its contract with the giant health insurance company. In a filing last month, United said that if the Justice Department's argument is right and Uni
The first patient was enrolled by Franco Fabbiocchi, M.D., director of Invasive Cardiology Unit IV at IRCCS Centro Cardiologico Monzino in Milan, Italy. The ILUMIEN IV trial will enroll up to 3,650 patients with high-risk, complex disease at 125 centers in North America, Europe and Asia to determine if OCT-guided stent procedures result in larger v
Albany, NY 04/13/2018 ADME-Tox is pharmacology term which stands for absorption, distribution, metabolism, and excretion with toxicity testing. These four criteria are important for the kinetics of drugs exposure to the tissue level, therefore testing ADME-Tox is crucial for drug development. ADME-Tox screening is system is an integrated work
Albertsons Cos. saw sales edge up for its 2017 fourth quarter and fiscal year as the supermarket retailer looks ahead to its planned merger with drug chain Rite Aid Corp.. For the quarter ended Feb. 24, overall sales rose 1.6% to $14.03 billion from $13.82 billion a year earlier, Albertsons reported in a filing with the Securities and Exchange Comm
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that data on a pharmacodynamic marker measured in its completed Phase 2 clinical trial evaluating lead product candidate A4250 in children with cholestatic liver disease and pruritus were presented today by trial...
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced new results from the Phase 1 and Phase 1/ 2 open-label extension studies of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias. These results were presented at the European Associat
Swiss pharmaceutical giant Novartis, on April 9th, agreed to acquire clinical-stage gene therapy company AveXis Inc. for $218 per share or a total approximate value of $8.7 billion. Alexion Pharmaceuticals, on April 11th, announced that is buying Sweden- based Wilson Therapeutics for $855 million in cash, in a bid to expand its rare disease therape
B. Braun Medical Inc., a leader in infusion therapy and pain management, announced today that it has received U.S. Food and Drug Administration approval for 0.9 percent Sodium Chloride Injection, USP in the Ecoflac (TM) Plus 500 mL container. Over the past few years, B. Braun worked closely with the FDA to temporarily import Ecoflac Plus under regu
Bellicum Pharmaceuticals, a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the U.S. Food and Drug Administration has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement on amendments to the st
CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that the China Food and Drug Administration has approved the Investigational New Drug application for a Phase II/III clinical study of lead candidate, CAN008. The company made public interim safety results from the..
Albany, NY 04/13/2018 The global chemiluminescence immunoassay analyzers market was valued over US$ 4.4 Bn in 2016 and is projected to register cumulative annual growth rate of over 6.0% from 2017 to 2025, according to a new report published by Transparency Market Research titled "Chemiluminescence Immunoassay Analyzers Market? The North Amer
The first medical device to use artificial intelligence in detecting diabetic retinopathy is coming soon in the market after getting an approval from the U.S. Food and Drug Administration. The device is significant in early detection of retinopathy, the common cause of blindness among the more than 30 million adults with diabetes. Before giving the
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. Today, the U.S. Food and Drug Administration took an important step to better protect consumers from the dangers of highly concentrated and pure caffeine products. The FDA is prepared to take steps right away to begin removing illegal
The FDA is planning to expand its abbreviated 510 program to lessen the burden of demonstrating substantial equivalence. In draft guidance, the FDA set out how sponsors can win approval for devices after showing they meet certain performance levels, rather than through direct comparisons with predicate products. The FDA introduced an abbreviated 51
"Global Chronic Lymphocytic Leukemia Therapeutics Market" Global Chronic Lymphocytic Leukemia Therapeutics Market By Cancer Type, Drug Type, Drugs, Route of Administration, By Geography Industry Trends and Forecast to 2024 Global Chronic Lymphocytic Leukemia Therapeutics Market accounted to grow at a CAGR of 18.73% during the forecast period of